Weinberg Adriana, Song Lin-Ye, Fenton Terence, Nachman Sharon A, Read Jennifer S, Patterson-Bartlett Julie, Levin Myron J
University of Colorado Denver, Aurora, 80045, USA.
AIDS Res Hum Retroviruses. 2010 Jan;26(1):51-9. doi: 10.1089/aid.2009.0163.
Live-attenuated influenza vaccine (LAIV) prevents significantly more cases of influenza in immune-competent children than the trivalent inactivated vaccine (TIV). We compared the T cell responses to LAIV or TIV in HIV-infected children. IFN-gamma-ELISPOT for the three vaccine-contained influenza strains, two mismatched strains, and phytohemagglutinin (PHA), was performed at 0, 4, and 24 weeks postimmunization in 175 HIV-infected children randomly assigned to LAIV or TIV. The contribution of CD8 T cells to the influenza-specific response (CD8-ELISPOT) was evaluated by CD8-cell depletion. CD8 T cells accounted for > or =87% of the total influenza-ELISPOT. At baseline, total influenza-ELISPOT and CD8-ELISPOT values were similar or higher in TIV compared with LAIV recipients. Four and 24 weeks after TIV, total influenza-ELISPOT and CD8-ELISPOT results were significantly lower than baseline results (p < or = 0.001). Responses to PHA also tended to decrease at 4 weeks after TIV (p = 0.06), but rebounded to baseline levels at 24 weeks. Four weeks after LAIV, total influenza-ELISPOT responses to vaccine-contained strains A H3N2 and B significantly decreased. Other ELISPOT values at 4 weeks and all values at 24 weeks were similar to the baseline values. At 4 and 24 weeks, TIV compared to LAIV administration resulted in a significantly greater decrease in influenza-specific ELISPOT values for vaccine-contained influenza A strains (p < or = 0.02). Responses to PHA also tended to decrease more in TIV recipients (p = 0.07). HIV-infected children immunized with TIV had significant and persistent decreases in ELISPOT responses to influenza. LAIV administration suppressed ELISPOT responses less. The clinical significance of these findings deserves further study.
与三价灭活疫苗(TIV)相比,减毒活流感疫苗(LAIV)能预防更多免疫功能正常儿童的流感病例。我们比较了HIV感染儿童对LAIV或TIV的T细胞反应。在175名随机分配接受LAIV或TIV的HIV感染儿童中,于免疫接种后0、4和24周,针对三种疫苗所含流感毒株、两种不匹配毒株以及植物血凝素(PHA)进行了γ干扰素-ELISPOT检测。通过CD8细胞耗竭评估CD8 T细胞对流感特异性反应(CD8-ELISPOT)的贡献。CD8 T细胞占流感-ELISPOT总数的≥87%。在基线时,与接受LAIV的儿童相比,接受TIV的儿童的总流感-ELISPOT和CD8-ELISPOT值相似或更高。TIV接种后4周和24周,总流感-ELISPOT和CD8-ELISPOT结果显著低于基线结果(p≤0.001)。TIV接种后4周对PHA的反应也有下降趋势(p = 0.06),但在24周时回升至基线水平。LAIV接种后4周,对疫苗所含甲型H3N2和乙型流感毒株的总流感-ELISPOT反应显著下降。4周时的其他ELISPOT值以及24周时的所有值与基线值相似。在4周和24周时,与LAIV接种相比,TIV接种导致疫苗所含甲型流感毒株的流感特异性ELISPOT值显著下降更多(p≤0.02)。TIV接种者对PHA的反应下降趋势也更明显(p = 0.07)。接受TIV免疫的HIV感染儿童对流感的ELISPOT反应显著且持续下降。LAIV接种对ELISPOT反应的抑制作用较小。这些发现的临床意义值得进一步研究。